Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1079 | 1031 | 1146 | 1074 | 1256 | 1982 |
Fund Return | 7.9% | 3.05% | 14.6% | 2.42% | 4.66% | 7.08% |
Place in category | 241 | 173 | 161 | 185 | 144 | 49 |
% in Category | 62 | 40 | 42 | 49 | 50 | 22 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
FC Responsible Global Equity 2 Acc | 1.33B | 5.81 | 6.53 | 12.17 | ||
FC Responsible Global Equity 4 Inc | 1.33B | 5.95 | 7.30 | 12.94 | ||
FC Responsible Global Equity 1 Acc | 1.33B | 5.68 | 5.70 | 11.23 | ||
FC Responsible Global Equity 1 Inc | 1.33B | 5.64 | 5.43 | 11.09 | ||
FC Responsible Global Equity Fund 2 | 1.33B | 11.03 | 2.96 | 12.15 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Liontrust Special Situations Fund R | 34.89M | -1.48 | 2.55 | 6.09 | ||
Liontrust Special Situations Fund A | 5.37M | 4.82 | 0.46 | 7.81 | ||
Liontrust Special Situations Fund I | 2.35B | 5.02 | 0.72 | 8.09 | ||
Fidelity Special Situations Fund W | 2.38B | 15.26 | 7.41 | 7.69 | ||
Fidelity Special Situations | 345.96M | -1.00 | 7.74 | 4.82 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
AstraZeneca | GB0009895292 | 7.88 | 9,990.0 | +0.05% | |
Unilever | GB00B10RZP78 | 5.07 | 54.20 | -0.95% | |
Experian | GB00B19NLV48 | 3.15 | 3,862.0 | -2.15% | |
GSK plc | GB00BN7SWP63 | 2.70 | 1,369.50 | -1.97% | |
Ashtead Group | GB0000536739 | 2.65 | 6,182.0 | -1.62% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Strong Sell | Neutral | Buy |
Technical Indicators | Strong Sell | Strong Sell | Strong Buy |
Summary | Strong Sell | Sell | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review